Parabolic Drugs Ltd. announced unaudited standalone earnings results for first quarter ended June 30, 2016. For the quarter, the company reported net sales/income from operations of INR 108.5 million compared to INR 215.5 million a year ago. Loss from operations before other income and finance costs and exceptional items was INR 454.2 million compared to INR 511.4 million a year ago. Loss from ordinary activities before tax of INR 773.1 million compared to INR 768.4 million a year ago. Net loss was INR 773.1 million or INR 12.49 basic and diluted per share before and after extraordinary items compared to INR 768.4 million or INR 12.42 basic and diluted per share before and after extraordinary itemsa year ago.